Blinklab (BB1.AU) Stock Analysis & Winston Score

Blinklab is a small Australian health technology company that makes a smartphone app designed to help detect neurodevelopmental conditions like autism and ADHD in children. The app works by measuring how a child's eyes respond to light and sound stimuli, turning a phone's camera into a simple screening tool. Its main customers are parents, pediatricians, and healthcare systems looking for faster, cheaper ways to identify these conditions early. The company earns revenue by licensing its software to healthcare providers and through partnerships with research institutions and clinics. Blinklab operates primarily in Australia and the Netherlands, where it has conducted clinical research, and is still in an early commercial stage with limited revenue. Its core advantage is its patented eye-blink reflex technology, which could allow screening without expensive specialist visits, but the main risk is that gaining regulatory approvals and convincing healthcare systems to adopt a new diagnostic tool is a slow and uncertain process.